Skip Navigation



Annals of Oncology Advance Access published online on March 15, 2008
Annals of Oncology, doi:10.1093/annonc/mdn050
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/7/1320    most recent
mdn050v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Capdeville, R.
Right arrow Articles by Gathmann, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capdeville, R.
Right arrow Articles by Gathmann, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias

R. Capdeville1,*, T. Krahnke1, A. Hatfield1, J. M. Ford1, I. Van Hoomissen2 and I. Gathmann1

1 Clinical Development, Novartis Oncology, Basel, Switzerland
2 PPD, Brussels, Belgium

* Correspondence to: Dr R. Capdeville, Clinical Development, Novartis Oncology, WSJ 103-3.09.09 CH-4002 Basel, Switzerland. Tel: +41-61-324-01-28; Fax: +41 61 324 00 46; E-mail: renaud.capdeville{at}novartis.com

Background: Imatinib is a selective inhibitor of the BCR/ABL tyrosine kinase. The remarkable initial results of the first phase I clinical trial published in 1999 prompted the rapid initiation of large phase II trials. They also generated intense media coverage and significant interest from patients and clinicians and demand for access to imatinib before marketing approval. In response, a worldwide expanded access program (EAP) for imatinib was implemented in May 2000.

Patients: In total, 7380 patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia failing prior therapies were enrolled in 106 centers in 34 countries.

Results: Time to progression and overall survival, as well as the safety profile, were similar to those observed in published phase II studies. At the end of the program, patients benefiting from treatment were continued on imatinib therapy by transferring to national health care systems or patient assistance programs.

Conclusion: The imatinib EAP successfully provided therapy to patients with CML before marketing approval. The program provides an efficient framework for the development of global EAPs for innovative investigational anticancer agents in patients without a satisfactory therapeutic alternative.

chronic myeloid leukemia (CML), expanded access program (EAP), Glivec, imatinib

Received for publication November 18, 2007. Revision received January 30, 2008. Accepted for publication February 1, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Capri, J. Chang, S.-C. Chen, P. Conte, K. Cwiertka, G. Jerusalem, Z. Jiang, S. Johnston, B. Kaufman, J. Link, et al.
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
Ann. Onc., November 2, 2009; (2009) mdp373v2.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.